Immunocore Excited to Engage with Investors at Key Conferences
Immunocore Engaging Investors Through Conferences
Immunocore Holdings plc (Nasdaq: IMCR), a biotechnology leader, is set to engage with the investment community at significant upcoming conferences in April. This opportunity allows the company to showcase its innovative immunomodulating therapies aimed at chronic diseases.
Upcoming Conferences
Management at Immunocore is scheduled to attend notable investor conferences, demonstrating the company’s commitment to transparency and investor communication.
Kempen Life Sciences Conference
This conference will feature one-on-one and small group meetings starting from April 3. It is an excellent chance for investors to gain insights directly from Immunocore’s leadership.
Needham Virtual Healthcare Conference
The following week, on April 9, Immunocore will participate in a Fireside Chat at 2:15 p.m. EDT. This format encourages an engaging dialogue about the company's strategic vision and pipeline developments.
Live Presentations Available
Interested parties can access the conference presentations live through Immunocore’s website, specifically in the ‘Events & Presentations’ section found under ‘Investors’. After the live sessions, replays will be available for those who wish to catch up on the discussions or missed the events.
About Immunocore
Immunocore is making significant strides with its pioneering TCR bispecific immunotherapy platform, known as ImmTAX (Immune mobilizing monoclonal TCRs Against X disease). This innovative approach is designed to tackle a wide array of conditions including cancer, autoimmune disorders, and infectious diseases.
The company is leveraging the ImmTAX technology to develop comprehensive pipelines across various therapeutic areas, with numerous clinical and pre-clinical studies currently underway. Immunocore's flagship therapy, KIMMTRAK, continues to be a cornerstone treatment for HLA-A*02:01-positive adult patients suffering from unresectable or metastatic uveal melanoma and has gained regulatory approvals in major regions worldwide including the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
If you're looking to learn more about Immunocore and its initiatives, get in touch with:
Sébastien Desprez
VP Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore
Investor Relations
Clayton Robertson / Morgan Warenius
T: +1 (215) 384-4781
E: ir@immunocore.com
Frequently Asked Questions
What is the purpose of the investor conferences?
The conferences provide a platform for Immunocore to share its advancements and engage directly with investors.
What products does Immunocore focus on?
Immunocore is focused on innovative immunotherapies to treat cancer, autoimmune diseases, and infectious conditions.
How does the ImmTAX platform work?
ImmTAX utilizes TCR bispecific immunotherapy to mobilize the immune system to target and treat various diseases more effectively.
Where can live presentations be accessed?
Live presentations can be accessed on Immunocore’s website under the ‘Events & Presentations’ section.
Who can I contact for more information?
For more information, you can reach out to Sébastien Desprez or the Investor Relations team via the provided email addresses.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.